Neuropsychiatric biotech raises $20M for PhII program

John Carroll The biotech is also planning to launch studies for SNC-102 in Tourette syndrome and post-traumatic stress syndrome. Accellient seeded Synchroneuron up to its $ 6 million ...

Rottapharm founders price IPO valuing company at up to $2.46 billion

Tracy Staton Two years ago, Rottapharm's founding family gave up on selling a big stake in the company. Word was, the offers didn't quite measure up to the asking price–and ...

Shire laments hole in EU food chain, Late-stage hit for GSK & Genmab, Lundbeck drug flunks PhIII

Nick Paul Taylor Welcome to the latest edition of our weekly EuroBiotech Report. With the battle for investor support in the AbbVie-Shire takeover tug of war heating up, the Ireland-headquartered ...

Zogenix puts Zohydro 2.0 into high gear, aiming to beat Purdue, Teva

Tracy Staton Zogenix knows it needs to step on the gas. If the company doesn't develop an abuse-resistant version of its controversial-and-powerful painkiller Zohydro–and ...

FDA promises a fast review for Boehringer’s lung disease contender

Damian Garde The FDA is guaranteeing a priority review for Boehringer Ingelheim's much-watched treatment for a rare lung disease, likely speeding up the drug's path to market ...

Takeda’s chief-in-waiting sees big M&A in the drugmaker’s future

Damian Garde Christophe Weber is next in line for the throne at Takeda, and the former GlaxoSmithKline exec has a mind to grow the Japanese pharma through dealmaking, hoping to refill ...

Study: Med students cozy with pharma reps more likely to dole out branded drugs

Emily Wasserman Doctors aren't the only ones to fall prey to free lunches and fuzzy promotional talks. Medical students who spend more time with& pharma reps are more likely ...

Nicox adds to eye-drug pipeline with $120M buyout deal for Aciex

John Carroll In a deal designed to beef up its pipeline of ophthalmology drugs, France's Nicox has snapped up Boston-based Aciex for $ 65 million in newly issued shares and up ...

France aims to save big bucks by subbing unapproved Avastin for eye drug Lucentis

Arlene Weintraub In June, the Italian government said it would pay for Roche's cancer drug Avastin to be used to treat a blinding eye disease, in place of the company's ...
Page 12 of 12« First...89101112
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS